Hims & Hers Health, Inc. (HIMS)
| Market Cap | 7.90B |
| Revenue (ttm) | 2.21B |
| Net Income (ttm) | 133.79M |
| Shares Out | 227.65M |
| EPS (ttm) | 0.54 |
| PE Ratio | 64.65 |
| Forward PE | 55.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,774,200 |
| Open | 33.54 |
| Previous Close | 33.62 |
| Day's Range | 32.88 - 34.99 |
| 52-Week Range | 21.36 - 72.98 |
| Beta | 2.40 |
| Analysts | Hold |
| Price Target | 44.56 (+28.38%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $44.56, which is an increase of 28.38% from the latest price.
News
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and...
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authori...
Hims & Hers names ex-FDA official Deb Autor as first policy chief
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Office...
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall...
Hims & Hers Bets on Lab Testing to Boost Growth
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
3 Overvalued Stocks to Sell
These are among the most overvalued stocks that Morningstar covers.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hen...
Hims & Hers: GLP-1 Partnership Could Unlock Value
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho...
HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform
Hims & Hers Health Inc (NYSE:HIMS) isn't just chasing wellness trends — it's building a global health platform. At the company's third-quarter earnings call, CEO Andrew Dudum said the company's next p...
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conf...
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow
The telehealth platform said revenue rose 49% to $599 million in the latest quarter.
Hims & Hers Stock Pops After Q3 Earnings: Here's Why
Hims & Hers Health, Inc. (NYSE:HIMS) shares popped after the company released its third-quarter earnings report after Monday's closing bell. Hims said it is in active discussions to make Novo Nordisk ...
Hims and Hers misses quarterly profit estimates
Hims and Hers Health missed Wall Street estimates for third-quarter profit on Monday, hit by increased product costs and reduced unit sales in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter...
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out...
Hims & Hers: Use This Drop Before It's Too Late
Hims & Hers has experienced a hefty sell-off in recent weeks. This sell-off was mainly caused by short-term turbulence, and I expect the company to resolve these issues in the next quarter. HIMS needs...
Hims & Hers: There's Opportunity In This Crash (Upgrade)
Hims & Hers offers a compelling "Buy" opportunity after a 30% pullback, despite recent growth concerns and insider selling. HIMS maintains strong long-term growth targets, aiming for $6.5 billion in r...
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Investors searching for the next Beyond Meat, Inc. (NYSE:BYND) — the latest poster child for explosive short squeezes — are eyeing the most shorted stocks as potential candidates for outsized rallies.
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm ...
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal...
Hims & Hers Health: Roller Coaster Gift
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, in...